Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes : comparison, efficacy and safety. / Deacon, Carolyn F; Holst, Jens Juul.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 15, 10.2013, p. 2047-58.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Deacon, CF & Holst, JJ 2013, 'Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety', Expert Opinion on Pharmacotherapy, vol. 14, no. 15, pp. 2047-58. https://doi.org/10.1517/14656566.2013.824966

APA

Deacon, C. F., & Holst, J. J. (2013). Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy, 14(15), 2047-58. https://doi.org/10.1517/14656566.2013.824966

Vancouver

Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy. 2013 Oct;14(15):2047-58. https://doi.org/10.1517/14656566.2013.824966

Author

Deacon, Carolyn F ; Holst, Jens Juul. / Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes : comparison, efficacy and safety. In: Expert Opinion on Pharmacotherapy. 2013 ; Vol. 14, No. 15. pp. 2047-58.

Bibtex

@article{4c5c4fcb338b444f9e8139727e452196,
title = "Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety",
abstract = "INTRODUCTION: Dipeptidyl peptidase (DPP)-4 inhibitors belong to one class of drugs that have been approved for treatment of type 2 diabetes (T2D) based on the glucose-lowering actions of the gastrointestinal hormone glucagon-like peptide (GLP)-1. Several different compounds are now available, and although their mechanism of action (inhibition of the catalytic activity of DPP-4) is the same, there are fundamental differences between them.AREAS COVERED: The authors discuss the differences between different DPP-4 inhibitors and review their therapeutic efficacy and key safety data. The literature covered includes original studies and meta-analyses identified in PubMed, recent abstracts presented at major diabetes scientific conferences, and clinical trials registered at ClinicalTrials.gov.EXPERT OPINION: Although there are some differences in the pharmacokinetic and pharmacodynamic profiles of the different DPP-4 inhibitors, all are small orally active compounds with broadly similar HbA1c-lowering efficacy. They improve glycaemic control in T2D, without increasing the risk of hypoglycaemia or causing weight gain. They can be used as monotherapy or in combination with other anti-diabetic therapies, including insulin, regardless of renal or hepatic function, and are efficacious across the spectrum of patients with T2D, including those with long-standing disease duration. DPP-4 inhibitors may also have beneficial effects beyond glycaemic control, although this remains to be demonstrated in purpose-designed clinical trials.",
keywords = "Animals, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Humans, Treatment Outcome",
author = "Deacon, {Carolyn F} and Holst, {Jens Juul}",
year = "2013",
month = "10",
doi = "10.1517/14656566.2013.824966",
language = "English",
volume = "14",
pages = "2047--58",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor & Francis",
number = "15",

}

RIS

TY - JOUR

T1 - Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes

T2 - comparison, efficacy and safety

AU - Deacon, Carolyn F

AU - Holst, Jens Juul

PY - 2013/10

Y1 - 2013/10

N2 - INTRODUCTION: Dipeptidyl peptidase (DPP)-4 inhibitors belong to one class of drugs that have been approved for treatment of type 2 diabetes (T2D) based on the glucose-lowering actions of the gastrointestinal hormone glucagon-like peptide (GLP)-1. Several different compounds are now available, and although their mechanism of action (inhibition of the catalytic activity of DPP-4) is the same, there are fundamental differences between them.AREAS COVERED: The authors discuss the differences between different DPP-4 inhibitors and review their therapeutic efficacy and key safety data. The literature covered includes original studies and meta-analyses identified in PubMed, recent abstracts presented at major diabetes scientific conferences, and clinical trials registered at ClinicalTrials.gov.EXPERT OPINION: Although there are some differences in the pharmacokinetic and pharmacodynamic profiles of the different DPP-4 inhibitors, all are small orally active compounds with broadly similar HbA1c-lowering efficacy. They improve glycaemic control in T2D, without increasing the risk of hypoglycaemia or causing weight gain. They can be used as monotherapy or in combination with other anti-diabetic therapies, including insulin, regardless of renal or hepatic function, and are efficacious across the spectrum of patients with T2D, including those with long-standing disease duration. DPP-4 inhibitors may also have beneficial effects beyond glycaemic control, although this remains to be demonstrated in purpose-designed clinical trials.

AB - INTRODUCTION: Dipeptidyl peptidase (DPP)-4 inhibitors belong to one class of drugs that have been approved for treatment of type 2 diabetes (T2D) based on the glucose-lowering actions of the gastrointestinal hormone glucagon-like peptide (GLP)-1. Several different compounds are now available, and although their mechanism of action (inhibition of the catalytic activity of DPP-4) is the same, there are fundamental differences between them.AREAS COVERED: The authors discuss the differences between different DPP-4 inhibitors and review their therapeutic efficacy and key safety data. The literature covered includes original studies and meta-analyses identified in PubMed, recent abstracts presented at major diabetes scientific conferences, and clinical trials registered at ClinicalTrials.gov.EXPERT OPINION: Although there are some differences in the pharmacokinetic and pharmacodynamic profiles of the different DPP-4 inhibitors, all are small orally active compounds with broadly similar HbA1c-lowering efficacy. They improve glycaemic control in T2D, without increasing the risk of hypoglycaemia or causing weight gain. They can be used as monotherapy or in combination with other anti-diabetic therapies, including insulin, regardless of renal or hepatic function, and are efficacious across the spectrum of patients with T2D, including those with long-standing disease duration. DPP-4 inhibitors may also have beneficial effects beyond glycaemic control, although this remains to be demonstrated in purpose-designed clinical trials.

KW - Animals

KW - Diabetes Mellitus, Type 2

KW - Dipeptidyl-Peptidase IV Inhibitors

KW - Humans

KW - Treatment Outcome

U2 - 10.1517/14656566.2013.824966

DO - 10.1517/14656566.2013.824966

M3 - Journal article

VL - 14

SP - 2047

EP - 2058

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -

ID: 132002658